These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

278 related items for PubMed ID: 32493400

  • 21. IGF1R inhibition in mammary epithelia promotes canonical Wnt signaling and Wnt1-driven tumors.
    Rota LM, Albanito L, Shin ME, Goyeneche CL, Shushanov S, Gallagher EJ, LeRoith D, Lazzarino DA, Wood TL.
    Cancer Res; 2014 Oct 01; 74(19):5668-79. PubMed ID: 25092896
    [Abstract] [Full Text] [Related]

  • 22. The inhibition of centromere protein K causes anticancer effects in breast carcinoma via effects on the FAK/PI3K/AKT/mTOR pathway.
    Yu J, Wang K, Yang S, Li G.
    Toxicol Appl Pharmacol; 2022 Nov 01; 454():116232. PubMed ID: 36089000
    [Abstract] [Full Text] [Related]

  • 23. Loss of Limb-Bud-and-Heart (LBH) attenuates mammary hyperplasia and tumor development in MMTV-Wnt1 transgenic mice.
    Ashad-Bishop K, Garikapati K, Lindley LE, Jorda M, Briegel KJ.
    Biochem Biophys Res Commun; 2019 Jan 08; 508(2):536-542. PubMed ID: 30509497
    [Abstract] [Full Text] [Related]

  • 24. Dual inhibition of PI3K and mTOR mitigates compensatory AKT activation and improves tamoxifen response in breast cancer.
    Chen X, Zhao M, Hao M, Sun X, Wang J, Mao Y, Zu L, Liu J, Shen Y, Wang J, Shen K.
    Mol Cancer Res; 2013 Oct 08; 11(10):1269-78. PubMed ID: 23814023
    [Abstract] [Full Text] [Related]

  • 25. Focal adhesion kinase governs cardiac concentric hypertrophic growth by activating the AKT and mTOR pathways.
    Clemente CF, Xavier-Neto J, Dalla Costa AP, Consonni SR, Antunes JE, Rocco SA, Pereira MB, Judice CC, Strauss B, Joazeiro PP, Matos-Souza JR, Franchini KG.
    J Mol Cell Cardiol; 2012 Feb 08; 52(2):493-501. PubMed ID: 22056317
    [Abstract] [Full Text] [Related]

  • 26. Baicalein Inhibits Gastric Cancer Cell Proliferation and Migration through a FAK Interaction via AKT/mTOR Signaling.
    Qiao D, Jin J, Xing J, Zhang Y, Jia N, Ren X, Lin Z, Jin N, Chen L, Piao Y.
    Am J Chin Med; 2021 Feb 08; 49(2):525-541. PubMed ID: 33641654
    [Abstract] [Full Text] [Related]

  • 27. Focal adhesion kinase contributes to proliferative potential of ErbB2 mammary tumour cells but is dispensable for ErbB2 mammary tumour induction in vivo.
    Lahlou H, Sanguin-Gendreau V, Frame MC, Muller WJ.
    Breast Cancer Res; 2012 Feb 28; 14(1):R36. PubMed ID: 22373082
    [Abstract] [Full Text] [Related]

  • 28. Buformin inhibits the stemness of erbB-2-overexpressing breast cancer cells and premalignant mammary tissues of MMTV-erbB-2 transgenic mice.
    Parris AB, Zhao Q, Howard EW, Zhao M, Ma Z, Yang X.
    J Exp Clin Cancer Res; 2017 Feb 13; 36(1):28. PubMed ID: 28193239
    [Abstract] [Full Text] [Related]

  • 29. Hyperactivation of mammalian target of rapamycin complex 1 (mTORC1) promotes breast cancer progression through enhancing glucose starvation-induced autophagy and Akt signaling.
    Chen Y, Wei H, Liu F, Guan JL.
    J Biol Chem; 2014 Jan 10; 289(2):1164-73. PubMed ID: 24275666
    [Abstract] [Full Text] [Related]

  • 30. p130Cas as a new regulator of mammary epithelial cell proliferation, survival, and HER2-neu oncogene-dependent breast tumorigenesis.
    Cabodi S, Tinnirello A, Di Stefano P, Bisarò B, Ambrosino E, Castellano I, Sapino A, Arisio R, Cavallo F, Forni G, Glukhova M, Silengo L, Altruda F, Turco E, Tarone G, Defilippi P.
    Cancer Res; 2006 May 01; 66(9):4672-80. PubMed ID: 16651418
    [Abstract] [Full Text] [Related]

  • 31. Quercetin suppresses the mobility of breast cancer by suppressing glycolysis through Akt-mTOR pathway mediated autophagy induction.
    Jia L, Huang S, Yin X, Zan Y, Guo Y, Han L.
    Life Sci; 2018 Sep 01; 208():123-130. PubMed ID: 30025823
    [Abstract] [Full Text] [Related]

  • 32. A novel methylated cation channel TRPM4 inhibited colorectal cancer metastasis through Ca2+/Calpain-mediated proteolysis of FAK and suppression of PI3K/Akt/mTOR signaling pathway.
    Wang C, Chen J, Kuang Y, Cheng X, Deng M, Jiang Z, Hu X.
    Int J Biol Sci; 2022 Sep 01; 18(14):5575-5590. PubMed ID: 36147460
    [Abstract] [Full Text] [Related]

  • 33. Vitronectin-αvβ3 integrin engagement directs hypoxia-resistant mTOR activity and sustained protein synthesis linked to invasion by breast cancer cells.
    Pola C, Formenti SC, Schneider RJ.
    Cancer Res; 2013 Jul 15; 73(14):4571-8. PubMed ID: 23722547
    [Abstract] [Full Text] [Related]

  • 34. Two distinct mTORC2-dependent pathways converge on Rac1 to drive breast cancer metastasis.
    Morrison Joly M, Williams MM, Hicks DJ, Jones B, Sanchez V, Young CD, Sarbassov DD, Muller WJ, Brantley-Sieders D, Cook RS.
    Breast Cancer Res; 2017 Jun 30; 19(1):74. PubMed ID: 28666462
    [Abstract] [Full Text] [Related]

  • 35. Inhibiting PI3K reduces mammary tumor growth and induces hyperglycemia in a mouse model of insulin resistance and hyperinsulinemia.
    Gallagher EJ, Fierz Y, Vijayakumar A, Haddad N, Yakar S, LeRoith D.
    Oncogene; 2012 Jul 05; 31(27):3213-22. PubMed ID: 22037215
    [Abstract] [Full Text] [Related]

  • 36. PI3K/AKT pathway regulates phosphorylation of steroid receptors, hormone independence and tumor differentiation in breast cancer.
    Riggio M, Polo ML, Blaustein M, Colman-Lerner A, Lüthy I, Lanari C, Novaro V.
    Carcinogenesis; 2012 Mar 05; 33(3):509-18. PubMed ID: 22180571
    [Abstract] [Full Text] [Related]

  • 37. Tumor-initiating function of nucleostemin-enriched mammary tumor cells.
    Lin T, Meng L, Li Y, Tsai RY.
    Cancer Res; 2010 Nov 15; 70(22):9444-52. PubMed ID: 21045149
    [Abstract] [Full Text] [Related]

  • 38. Mammary tumors initiated by constitutive Cdk2 activation contain an invasive basal-like component.
    Corsino PE, Davis BJ, Nørgaard PH, Parker NN, Law M, Dunn W, Law BK.
    Neoplasia; 2008 Nov 15; 10(11):1240-52. PubMed ID: 18953433
    [Abstract] [Full Text] [Related]

  • 39. Modulation of tumor fatty acids, through overexpression or loss of thyroid hormone responsive protein spot 14 is associated with altered growth and metastasis.
    Wellberg EA, Rudolph MC, Lewis AS, Padilla-Just N, Jedlicka P, Anderson SM.
    Breast Cancer Res; 2014 Dec 04; 16(6):481. PubMed ID: 25472762
    [Abstract] [Full Text] [Related]

  • 40. Mechanism of inhibition of MMTV-neu and MMTV-wnt1 induced mammary oncogenesis by RARalpha agonist AM580.
    Lu Y, Bertran S, Samuels TA, Mira-y-Lopez R, Farias EF.
    Oncogene; 2010 Jun 24; 29(25):3665-76. PubMed ID: 20453882
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 14.